One of the largest international scientific research programs on epilepsy has reached its end. The EPISTOP project proved that preventive treatment decreased the risk and severity of epilepsy. The results of the EPISTOP research will be used to develop a new roadmap of recommendations for the detection and treatment of epilepsy around the world.

Around 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases. To decrease this figure and pave the way for future ground-breaking epilepsy research, seven large EU-funded projects joined forces in May 2018 in Brussels, Belgium, in a unique community-building event – the epiXchange conference. Designed to gather a critical mass of epilepsy researchers and stakeholders, the conference became a forum for exchange and discussions on latest research results and future research policies.

The epiXchange cluster has now published an article in Epilepsia, presenting major achievements by the cluster in the areas of biomarkers, genetics, therapeutics, comorbidities and biobanks as well as recommendations for future research to develop and bring novel solutions to the patients. To read the article, click here.

More information about the epiXchange event can be found here.

The EPISTOP project seeks to develop new biomarkers of epilepsy and to identify new therapeutic targets
to block or otherwise modify epileptogenesis in humans. The findings could significantly improve the disease
burden of epileptic patients around the world... read more (PDF)

Prof. Steve Roach, neurologist at the Dell Medical School University of Texas, sent a comment on the results obtained within the EPISTOP project.

On April 4, the EPISTOP results were shared during our closing conference in Warsaw (Poland). 

For the official press release, click here

 DSC3861

 DSC3779

 DSC3897

 DSC3960

 DSC3979

 DSC4021

 DSC4063

 DSC4275

 DSC4355

 DSC4358

 DSC4315